Your browser doesn't support javascript.
loading
Two challenging cases of anti-MDA-5 dermatomyositis with rapidly progressive interstitial lung disease.
Biddle, Kathryn; Agaoglu, Elif; Brent, Geoffrey; Adam, John; Nockels, Rachel; Loveridge, Adam; Bazari, Farid; Natkunarajah, Janakan; Al-Shakarchi, Israa.
  • Biddle K; St George's University of London, Infection and Immunity, Cranmer Terrace, London, SW17 0RE, UK.
  • Agaoglu E; Kingston Hospital NHS Foundation Trust, Rheumatology, Kingston upon Thames, KT2 7QB, UK.
  • Brent G; Kingston Hospital NHS Foundation Trust, Respiratory, Kingston upon Thames, KT2 7QB, UK.
  • Adam J; Kingston Hospital NHS Foundation Trust, Dermatology, Kingston upon Thames, KT2 7QB, UK.
  • Nockels R; Kingston Hospital NHS Foundation Trust, General Medicine, Kingston upon Thames, KT2 7QB, UK.
  • Loveridge A; Kingston Hospital NHS Foundation Trust, General Medicine, Kingston upon Thames, KT2 7QB, UK.
  • Bazari F; Kingston Hospital NHS Foundation Trust, Respiratory, Kingston upon Thames, KT2 7QB, UK.
  • Natkunarajah J; Kingston Hospital NHS Foundation Trust, Respiratory, Kingston upon Thames, KT2 7QB, UK.
  • Al-Shakarchi I; Kingston Hospital NHS Foundation Trust, Dermatology, Kingston upon Thames, KT2 7QB, UK.
Oxf Med Case Reports ; 2024(6): omae061, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38860011
ABSTRACT
Anti-MDA-5 dermatomyositis (DM) is a subtype of idiopathic inflammatory myopathy, commonly presenting as clinically amyopathic dermatomyositis. It is associated with rapidly progressive interstitial lung disease and a poor prognosis. Here, we present two cases of anti-MDA-5 DM and discuss the challenges associated with timely diagnosis, and the importance of early and aggressive treatment.
Palabras clave